The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: A preliminary study

International Journal of Rheumatic Diseases

Volumn 13, Issue 1, 2010, Pages 48-54

  Lee, Hee Ji ^a   Waller, Rosmary D ^b   Stebbings, Simon ^b   Highton, John ^b   Orlovich, David A ^a   Schmierer, David ^a   Fawcett, J Paul ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Gut microbiota; Metabolism; Probiotics; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; MESALAZINE; N ACETYLSULFAPYRIDINE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DENATURING GRADIENT GEL ELECTROPHORESIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENTIATION; FECES ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; URINALYSIS;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIFIDOBACTERIUM; BIOTRANSFORMATION; DRUG INTERACTIONS; FECES; FEMALE; HUMANS; LACTOBACILLUS ACIDOPHILUS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; STREPTOCOCCUS; SULFAPYRIDINE; SULFASALAZINE;

EID: 75649147873     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2009.01449.x     Document Type: Article

References (36)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001, 358:903-11.
2. Lipsky PE, van der Heijde DM, St Clair EW. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-602.
3. O'Dell JR, Haire CE, Erikson N. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996, 334:1287-91.
4. Wilson K, Brydon S. The Pharmaceutical Schedule 2009, eds, Volume 16 Number 2, Pharmaceutical Management Agency, Wellington, New Zealand, Accessed October, 2009
5. Azad Khan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol 1982, 13:523-8.
6. Schröder H, Evans DA. Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 1972, 13:278-84.
7. Das KM, Eastwood MA, McManus JP. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973, 289:491-5.
8. Pullar T, Hunter JA, Capell HA. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis. Ann Rheum Dis 1985, 44:831-7.
9. Azad Khan A, Guthrie G, Johnston HH. Tissue and bacterial splitting of sulphasalazine. Clin Sci (Lond) 1983, 64:349-54.
10. Soleim HA, Scheline RR. Metabolism of xenobiotics by strains of intestinal bacteria. Acta Pharmacol Toxicol (Copenh) 1972, 31:471-80.
11. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972, 181:555-62.
12. Das KM, Eastwood MA, McManus JP. The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut 1973, 14:631-41.
13. Guidelines for the evaluation of probiotics in food. 2002, http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf, Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada, April 30 and May 1, 2002. Accessed 4 July 2009
14. Hatakka K, Martio J, Korpela M. Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis-a pilot study. Scand J Rheumatol 2003, 32:211-5.
15. Nenonen MT, Helve TA, Rauma AL. Uncooked, lactobacilli-rich, vegan food and rheumatoid arthritis. Br J Rheumatol 1998, 37:274-81.
16. Mikov M, Lee HJ, Fawcett JP. The influence of probiotic treatment on sulfasalazine metabolism in rat gut contents. Asian J Pharmacokinet Pharmacodyn 2006, 6:337-42.
17. Reid G. Safe and efficacious probiotics: what are they? Trends Microbiol 2006, 14:348-52.
18. Holzapfel WH, Haberer P, Snel J. Overview of gut flora and probiotics. Int J Food Microbiol 1998, 41:85-101.
19. Fooks LJ, Gibson GR. Probiotics as modulators of the gut flora. Br J Nutr 2002, 88:S39-49.
20. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-24.
21. Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994, 37:470-5.
22. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986, 25:206-9.
23. Ahnfelt NO, Modin R, Odell ML. Determination of salicylazosulphapyridine, sulphapyridine and its metabolites in serum and urine. J Pharm Biomed Anal 1986, 4:261-9.
24. Chungi VS, Rekhi GS, Shargel L. A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids. J Pharm Sci 1989, 78:235-8.
25. Walter J, Tannock GW, Tilsala-Timisjarvi A. Detection and identification of gastrointestinal Lactobacillus species by using denaturing gradient gel electrophoresis and species-specific PCR primers. Appl Environ Microbiol 2000, 66:297-303.
26. Anderson CM, Haygood MG. α-Proteobacterial symbionts of marine bryozoans in the genus Watersipora. Appl Environ Microbiol 2007, 73:303-11.
27. Bechtel YC, Bonaiti-Pellie C, Poisson N. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993, 54:134-41.
28. Farr M, Waterhouse L, Johnson AE. A double-blind controlled study comparing sulphasalazine with placebo in rheumatoid factor (RF)-negative rheumatoid arthritis. Clin Rheumatol 1995, 14:531-6.
29. Hannonen P, Möttönen T, Hakola M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993, 36:1501-9.
30. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 2005, 65:1825-49.
31. Goldin BR, Swenson L, Dwyer J. Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes. J Natl Cancer Inst 1980, 64:255-61.
32. Goossens D, Jonkers D, Russel M. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment Pharmacol Ther 2003, 18:495-505.
33. Larsen CN, Nielsen S, Kaestel P. Dose-response study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 2006, 60:1284-93.
34. Azad Khan AK, Nurazzaman M, Truelove SC. The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. J Med Genet 1983, 20:30-6.
35. Das KM, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1976, 1:406-25.
36. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J. Probiotics for treating eczema. Cochrane Database Syst Rev 2008, 10.1002/14651858.CD006135.pub2, DOI